Immunology Presentations

Introduction to Immunology

Antibody Structure and B Cell Diversity

Antigen Recognition by T Lymphocytes

Development of B Lymphocytes

Development of T Lymphocytes

T Cell Mediated Immunity (CMI)

Immunity Mediated by B Cells and Antibodies

Defense Mechanisms of Human Host

Failure of Human Defense Mechanisms

HIV Infection and AIDS

Allergy and Hypersensitivity

Autoimmunity and Autoimmune Diseases

Case Studies in Autoimmunity

Rheumatoid Arthritis

Systemic Lupus Erythymatosus

Case Studies in Autoimmunity

Multiple Sclerosis

Myasthenia Gravis

Vaccines and Vaccination

Transplantation of Tissue and Organs

Read more...

Umbilical Cord Blood transplantation in acute leukemias

Umbilical Cord Blood transplantation in acute leukemias
Presentation by: Pablo Ramirez, M.D.
DiPersio Lab
Grand Rounds, March 2009

Topics covered are:
Clinical case
High risk cytogenetics: matched donor vs chemo
Impact of HLA mismatch on OS
Unrelated cord donor
Cord blood-derived stem cell source
First human infusion
Collection, processing and storage of UCB
Biology UCBT:
more questions than answers
Transplantation with UCB: children
Outcomes unrelated UCB vs BM: children with acute leukemia CIBMTR-USA
Probability of LFS
Transplantation with UCB: adults
Comparison between UCBT-uBMT:
European database analysis
Neutrophil recovery
Comparison between UCBT-uBMT American database analysis
Neutrophil recovery
Platelet recovery
Comparison of uBM, PB and UCB:
Conclusions from these studies and other databases
Approaches to improve rates and kinetics of engraftment
Transplantation of 2 partially HLA-matched UCB units (U of MN):
Myeloablative
Demographics
Neutrophil engraftment
Always one cord predominated: Potential contributors
GVHD
Hematologic recovery
Netrophils
Platelets
Chimerism
Higher incidence of grade II-IV aGVHD
Risk factors for TRM
Conclusions
Unresolved questions in UCBT


Umbilical Cord Blood transplantation in acute leukemias.ppt

Read more...

Immune Modulation for Prevention of Type 1 Diabetes

Immune Modulation for Prevention of Type 1 Diabetes
Presentation by: Peter A. Gottlieb, MD
Barbara Davis Center
University of Colorado Health Sciences Center Denver, CO


Main Points

* Type 1 diabetes is an autoimmune disease
* It is a predictable disease with different phases
* Approaches to prevention and cure are possible.
* New insulins, medications and devices will improve therapy in the coming decade.

Regulatory Cells
Cellular Mechanics of Autoimmune Type 1 Diabetes
Progression to Diabetes vs Number of Autoantibodies
Type 1a Diabetes: An Autoimmune Disorder
Prevention of Type 1 diabetes
Secondary Prevention
EDIC: Long Term Benefit of Intensive Treatment
Diabetes Control and Complications Trial
Past Trials in New Onset Type 1
Metabolic Effects of AZA and Prednisone at 1 year in New Onset T1DM
Ongoing and Proposed Non-antigen Specific Immunotherapy Trials in New Onset Type 1 DM
Preservation of Pancreatic Production of Insulin (POPPI) study
(Mycophenolate Mofetil and Zenapax)
Mycophenolate Mofetil (MMF)
MMF (CellCept)
MMF Toxicities
Activated T cell
POPPI Study
Potential Benefits of the Study
Control Group
Before treatment
1 wk after treatment
Induction of IL-10+CD4+ cells in vivo following
Treatment with hOKT3g1(Ala-Ala)
Antigen Specific Therapy
Insulin
Altered Peptide Ligand
Recent and Ongoing Antigen-specific Immunotherapy Trials in T1DM
Prediabetes
Primary Prevention
Rationale for Oral Insulin
Oral Antigen Protocol
Nutritional Intervention to Prevent
Mechanistic Studies
Key Elements of Successful Clinical Trials

Immune Modulation for Prevention of Type 1 Diabetes.ppt

Read more...